PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment

[1]  Xiaozheng Xu,et al.  PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. , 2019, Immunity.

[2]  P. Kim,et al.  A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery , 2019, Proceedings of the National Academy of Sciences.

[3]  T. Irie,et al.  Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity , 2019, Clinical Cancer Research.

[4]  T. Okazaki,et al.  Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses , 2019, Science.

[5]  P. Bankhead,et al.  Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells , 2019, Front. Immunol..

[6]  G. Kiss,et al.  RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers , 2018, Nature Cell Biology.

[7]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[8]  J. Lunceford,et al.  PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer , 2017, Clinical Cancer Research.

[9]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[10]  Ronald D. Vale,et al.  T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition , 2016, Science.

[11]  Ludmila V. Danilova,et al.  Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors , 2016, Proceedings of the National Academy of Sciences.

[12]  Ryan L. Kelly,et al.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.

[13]  Ping Zhu,et al.  Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases , 2016, Nature.

[14]  G. Freeman,et al.  Coinhibitory Pathways in Immunotherapy for Cancer. , 2016, Annual review of immunology.

[15]  Takeharu Nagai,et al.  Expanded palette of Nano-lanterns for real-time multicolor luminescence imaging , 2015, Proceedings of the National Academy of Sciences.

[16]  Takashi Saito,et al.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2 , 2012, The Journal of experimental medicine.

[17]  K. Okumura,et al.  Antibodies against B7-DC with differential binding properties exert opposite effects. , 2012, Hybridoma.

[18]  I. Salmon,et al.  Reviving Function in CD4+ T Cells Adapted to Persistent Systemic Antigen1 , 2009, The Journal of Immunology.

[19]  Michael Loran Dustin,et al.  Spatiotemporal regulation of T cell costimulation by TCR-CD28 microclusters and protein kinase C theta translocation. , 2008, Immunity.

[20]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[21]  Takashi Saito,et al.  Newly generated T cell receptor microclusters initiate and sustain T cell activation by recruitment of Zap70 and SLP-76 , 2005, Nature Immunology.

[22]  Rajat Varma,et al.  Actin and agonist MHC–peptide complex–dependent T cell receptor microclusters as scaffolds for signaling , 2005, The Journal of experimental medicine.

[23]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[24]  Michael Cammer,et al.  Structural and functional analysis of the costimulatory receptor programmed death-1. , 2004, Immunity.

[25]  K. Sheppard,et al.  PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. , 2004, FEBS letters.

[26]  Drew M Pardoll,et al.  Differential binding properties of B7-H1 and B7-DC to programmed death-1. , 2003, Biochemical and biophysical research communications.

[27]  津島 文彦.  Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses , 2003 .

[28]  Tetsuo Yamazaki,et al.  T cell receptor ligation induces the formation of dynamically regulated signaling assemblies , 2002, The Journal of cell biology.

[29]  T. Okazaki,et al.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[31]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[32]  S. Bromley,et al.  The immunological synapse: a molecular machine controlling T cell activation. , 1999, Science.

[33]  Colin R. F. Monks,et al.  Three-dimensional segregation of supramolecular activation clusters in T cells , 1998, Nature.

[34]  T. Honjo,et al.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. , 1996, International immunology.

[35]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.